Partial reprogramming by cyclical overexpression of Yamanaka factors improves pathological phenotypes of tauopathy mouse model of human Alzheimer's disease.
Level 5 - mechanism / opinion, no new human data
Animal study without human clinical data
PubMed 40021076 · doi:10.1016/j.pneurobio.2025.102743
What was done
Researchers created a transgenic mouse model carrying the Tau-P301S mutation and doxycycline-inducible Yamanaka factors to test whether cyclical, controlled partial cellular reprogramming affects tauopathy development. Following induction, they evaluated hippocampal tau pathology, reactive astrogliosis, age-related changes in the H3K9me3 epigenetic marker, and spatial memory.
What was found
The abstract reports directional outcomes without exact numerical data or effect sizes. Inducible cyclical overexpression of Yamanaka factors led to reversed tauopathy in the hippocampus, alleviated reactive astrogliosis, counteracted age-related reduction of H3K9me3, and improved spatial memory performance.
Why it matters
This study provides preclinical evidence that in vivo cyclical partial reprogramming can ameliorate pathological hallmarks and cognitive deficits in a standard genetic model of tauopathy.
Limits
The study was conducted entirely in a transgenic mouse model (P301S), limiting direct applicability to human Alzheimer's disease. The abstract does not disclose sample sizes (n), quantitative effect sizes, dosing/cycling schedules, or assessments of potential long-term risks such as oncogenesis or teratoma formation.
Cited by
- partial Reversing the biological age of the brain in mouse models of Alzheimer's disease causes the disease and dementia symptoms to resolve.